Business Context and Reporting Period
This Form 8-K Current Report was filed by Mannatech, Incorporated on July 1, 2024. The filing announces a significant change in executive leadership, specifically the appointment of a new Chief Financial Officer (CFO) effective July 1, 2024.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and employment terms.
- Annual Base Salary (New CFO): $275,000
- Stock Option Grant: 4,500 shares of common stock
- Relocation Allowance: $15,000 (one-time)
Material Changes
The primary material change is the appointment of James Clavijo as Chief Financial Officer, principal financial officer, and principal accounting officer. Landen Fredrick, the Chief Executive Officer, who served as interim CFO since January 2024, has relinquished the CFO role to Mr. Clavijo.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. It details Mr. Clavijo's background, noting over 25 years of experience in executive finance roles within biotech, pharmaceutical, and healthcare sectors. The filing also outlines severance provisions under the new employment agreement, which apply if the Company terminates the agreement early or chooses not to renew it.
Investor Verification Checklist
- Verify the formal execution of the stock option grant for 4,500 shares under the 2017 Stock Incentive Plan.
- Review the full Executive Employment Agreement (Exhibit 10.20) for specific details on bonus program eligibility and severance triggers.
- Confirm the transition timeline for financial reporting responsibilities between the interim and permanent CFO.